

T-CELL RESPONSES

Reversing exhaustion



Feeling the effects of a relentless and overloaded schedule? T cells also suffer from exhaustion and are less effective at doing their job when faced with persistent antigen, such as during chronic viral infection or cancer. Now, researchers reporting in *Nature* describe a mechanism that reverses the CD8⁺ T-cell exhaustion seen in chronic infection of mice with lymphocytic choriomeningitis virus (LCMV) and restores the ability of T cells to control the virus.

LCMV is a natural pathogen of mice and, importantly for this study, strains are available that cause either

acute (the Armstrong strain) or chronic (the clone 13 strain) infection. Therefore, infection with the Armstrong strain is cleared within a week and a stable pool of long-lived memory T cells is established. By contrast, the clone 13 strain establishes a persistent infection, which overwhelms the immune response and results in the generation of functionally impaired or exhausted virus-specific CD8⁺ T cells.

To study T-cell dysfunction in chronic infection, Rafi Ahmed and colleagues first carried out gene-expression analysis of T cells that were generated following infection with each LCMV strain. Most notably, the exhausted virus-specific CD8⁺ T cells contained more mRNA encoding the inhibitory receptor PD1 (programmed death 1; also known as PDCD1) than functional virus-specific CD8⁺ T cells from Armstrong-strain-infected mice. Further analysis showed that although PD1 was transiently expressed by CD8⁺ T cells after infection with the Armstrong strain, it was rapidly downregulated, whereas CD8⁺ T cells responding to the clone 13 strain retained high PD1 expression throughout the chronic infection. Moreover, one of the ligands for PD1, PDL1, was shown to be highly expressed by persistently infected splenocytes, indicating that this inhibitory

receptor–ligand interaction might regulate T-cell function during chronic LCMV infection.

To test this, the authors treated persistently infected mice with a blocking antibody specific for PDL1. Remarkably, compared with untreated mice, chronically infected mice that were treated with PDL1-specific antibody underwent a marked expansion of virus-specific CD8⁺ T-cell populations, which had an increased ability to produce interferon- γ and tumour-necrosis factor, thereby reversing the exhausted phenotype. In addition, PDL1 blockade markedly reduced the viral load and resolved infection with the clone 13 strain.

The authors then showed that, even in mice that lack CD4⁺ T cells and therefore suffer from a more severe form of chronic infection and T-cell exhaustion, PDL1 blockade could reverse the functional impairment of the exhausted T cells and reduce the viral load. This might be of particular relevance for HIV infection, which is characterized by a loss of CD4⁺ T cells.

Although, on the basis of these results, blockade of the PD1–PDL1 pathway for the treatment of chronic viral infection or cancer is tantalizing, prolonged disruption of this regulatory pathway can result in autoimmunity, as exemplified by PDL1-deficient mice.

Lucy Bird

ORIGINAL RESEARCH PAPER Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* **439**, 682–687 (2006)

FURTHER READING Williams, M. A. & Bevan, M. J. Exhausted T cells perk up. *Nature* **439**, 669–670 (2006)

RESEARCH HIGHLIGHTS ADVISORS

CEZMI AKDIS Swiss Institute of Allergy and Asthma Research, Davos, Switzerland
BRUCE BEUTLER The Scripps Research Institute, La Jolla, USA
PETER CRESSWELL Yale University, New Haven, USA

JAMES DI SANTO Institut Pasteur, Paris, France
GARY KORETZKY University of Pennsylvania, Philadelphia, USA
CHARLES MACKAY Garvan Institute of Medical Research, Sydney, Australia

CORNELIS MELIEF Leiden University Medical Center, Leiden, The Netherlands
MICHEL NUSSENZWEIG The Rockefeller University, New York, USA
RICHARD RANSOHOFF The Cleveland Clinic Foundation, Cleveland, USA

ALAN SHER National Institute of Allergy and Infectious Diseases, Bethesda, USA
ANDREAS STRASSER The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

MEGAN SYKES Harvard Medical School, Boston, USA
ERIC VIVIER Centre d'Immunologie de Marseille-Luminy, Marseille, France
MATTHIAS VON HERRATH La Jolla Institute for Allergy and Immunology, San Diego, USA